The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: A clustered systematic review and meta-analysis

医学 恶性胸腔积液 胸膜成形术 内科学 荟萃分析 胸腔积液 中医药 随机对照试验 肿瘤科 病理 替代医学
作者
Cheng-Qiong Wang,Jiao Xu,Hong Jiang,Xiao-Tian Zheng,Yan Zhang,Xiao-Rong Huang,Fei She,Teng-Yang Fan,Lin Zhan,Jihong Feng,Qihai Gong,Xue Xiao,Xiaofan Chen,Zheng Xiao
出处
期刊:Phytomedicine [Elsevier]
卷期号:115: 154847-154847 被引量:5
标识
DOI:10.1016/j.phymed.2023.154847
摘要

Aidi injection (Aidi), a traditional Chinese medicine injection, is often practiced to control malignant pleural effusion (MPE). We performed a registered systematic review and meta-analysis (PROSPERO: CRD42022337611) to clarify the clinical role of Aidi in MPE, reveal optimal combinations of Aidi and chemical agents, their indications, therapeutic route and usage, and demonstrate their clinical effectiveness and safety. All randomized controlled trials (RCTs) about Aidi in controlling MPE were collected from Chinese and English databases (up to October 2022). We clustered them into multiple homogenous regimens, evaluated the risk-of-bias at outcome level using a RoB 2, extracted and pooled the data using meta-analysis or descriptive analysis, and finally summarized their evidence quality. All 56 studies were clustered into intrapleural administration with Aidi alone or plus chemical agents, and intravenous administration with Aidi for MPE. Intrapleural administration with Aidi alone displayed similar clinical responses on Cisplatin (DDP) alone. Only administration with Aidi plus DDP significantly improved complete response and quality of life, and displayed a low pleurodesis failure, disease progression, hematotoxicity, gastrointestinal and hepatorenal toxicity. For patients with moderate to massive effusion, Karnofsky Performance Status score ≥ 50 or anticipated survival time ≥3 months, Aidi (50 ml to 80 ml each time, one time each week and three to eight times) plus DDP (20 to 30 mg, 40 to 50 mg, or 60 to 80 mg each time) significantly improved clinical responses. Most results had moderate to low quality. Current evidences indicate that Aidi, a pleurodesis agent, plays an interesting clinical role in controlling MPE. Aidi plus DDP perfusion is a most commonly used regimen, which shows a significant improvement in clinical responses. These findings also provide an indication and possible optimal usage for rational drug use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光亮雨完成签到 ,获得积分10
1秒前
ZeKwi完成签到,获得积分10
1秒前
Asteria完成签到,获得积分10
1秒前
2秒前
衫楠如画完成签到,获得积分10
3秒前
4秒前
wcd发布了新的文献求助10
5秒前
Novoa应助科研通管家采纳,获得10
6秒前
Nicey_W应助科研通管家采纳,获得10
6秒前
浮游应助科研通管家采纳,获得10
6秒前
今后应助科研通管家采纳,获得10
6秒前
浮游应助科研通管家采纳,获得10
6秒前
spc68应助科研通管家采纳,获得10
7秒前
Ava应助科研通管家采纳,获得10
7秒前
7秒前
研友_VZG7GZ应助科研通管家采纳,获得10
7秒前
spc68应助科研通管家采纳,获得10
7秒前
浮游应助科研通管家采纳,获得10
7秒前
华仔应助科研通管家采纳,获得10
7秒前
teeth发布了新的文献求助10
8秒前
浮游应助科研通管家采纳,获得10
8秒前
搜集达人应助科研通管家采纳,获得10
8秒前
Hello应助科研通管家采纳,获得10
8秒前
lilili应助科研通管家采纳,获得10
8秒前
spc68应助科研通管家采纳,获得10
8秒前
情怀应助科研通管家采纳,获得10
8秒前
华仔应助科研通管家采纳,获得10
9秒前
枫cxf163应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
科研通AI6应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
NexusExplorer应助科研通管家采纳,获得10
9秒前
9秒前
jingle给jingle的求助进行了留言
9秒前
幽默果汁完成签到 ,获得积分10
9秒前
9秒前
9秒前
白假完成签到,获得积分20
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1000
Russian Foreign Policy: Change and Continuity 800
Real World Research, 5th Edition 800
Qualitative Data Analysis with NVivo By Jenine Beekhuyzen, Pat Bazeley · 2024 800
Superabsorbent Polymers 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5712031
求助须知:如何正确求助?哪些是违规求助? 5207432
关于积分的说明 15266074
捐赠科研通 4864074
什么是DOI,文献DOI怎么找? 2611194
邀请新用户注册赠送积分活动 1561461
关于科研通互助平台的介绍 1518793